During the first quarter of 2019, Samsung Bioepis’ biosimilars revenue increased to $175 million, up from $128 million in the first quarter of 2018. Those numbers, say Biogen, are driven by the launch of biosimilar adalimumab, Imraldi.
During the first quarter of 2019, Samsung Bioepis’ biosimilars revenue increased to $175 million, up from $128 million in the first quarter of 2018. Those numbers, say Biogen, are driven by the launch of biosimilar adalimumab, Imraldi.
Biogen, which together with its partner Samsung BioLogics forms Samsung Bioepis, reported its first quarter 2019 financial results on April 24.
The partnership has 3 biosimilars that are currently in the marketplace: a biosimilar etanercept (Benepali) referencing Enbrel; Imraldi, referencing Humira; and a biosimilar infliximab, sold as Flixabi in the European Union and as Renflexis in the United States, referencing Remicade.
Benepali sales were up 3% year over year, for a total of $124 million in revenue. Flixabi was up 123% year over year, for $15 million in revenue. Imraldi, which was launched in October 2018, was up 114% quarter over quarter, for $36 million in revenue.
These numbers come after reports that biosimilar adalimumab in general—and Imraldi in particular—are off to a strong start in Europe. IQVIA data released in the first quarter of the year show that in Germany, which had the most biosimilar adalimumab options available in November 2018, the greatest percentages of patients who switched from Humira to another option were transitioned to Imraldi (37%). Sandoz’s Hyrimoz and Amgen’s Amgevita trailed behind at 15% and 12%, respectively.
In the United Kingdom, which was responsible for the most consumption of brand-name Humira in the European Union as of September 2018, Imraldi was awarded 45% of the market via a centralized tender. Amgevita and Sandoz were each awarded roughly one-fourth of the market, and Mylan’s Hulio was awarded approximately 5% of the market.
According to IQVIA, “It is Samsung with Imraldi that has won out so far in the 2 markets that matter the most: Samsung has the largest potential market in the United Kingdom and has shown the most success in acquiring Humira patients in Germany.”
Samsung Bioepis continues to develop other biosimilar agents; currently in the drug maker’s pipeline are FDA- and European Medicines Agency—approved trastuzumab biosimilar Ontruzant, a bevacizumab biosimilar undergoing a phase 3 study, a ranibizumab biosimilar undergoing a phase 3 study, and an eculizumab biosimilar currently in phase 1 clinical trials.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.